Treatment of neurological diseases
View Patent ↗Aspects and embodiments of the present invention relate to the treatment of neurological disorders such as for example, Alzheimer's disease and Parkinson's disease. Particularly, certain embodiments relate to GIP/GLP-1 co-agonist peptides for use in the treatment of these two neurological disorders. Also included in the present invention are inter alia pharmaceutical compositions comprising the GIP/GLP-1 co-agonist peptides, together with methods of treating such disorders as well as other subject matter.
1. A glucose-dependent insulinotropic peptide/glucagon-like peptide 1 (GIP/GLP-1) co-agonist peptide
which consists of the amino acid sequence of:
YXEGTFTSDYSIYLDKQAAXEFVNWLLAGGPSSGAPPPSKKKKKK-NH 2 (SEQ. ID. No. 11) wherein X=aminoisobutyric acid, or
which consists of the amino acid sequence of:
YXEGTFTSDYSIYLDKQAAXEFVNWLLAGGPSSGAPPPSKRRQRRKKRGY-NH 2 (SEQ. ID. No. 12) wherein X=aminoisobutyric acid.
2. A process for the treatment of a neurological disorder selected from the group consisting of Alzheimer's disease and Parkinson's disease in a subject in need thereof comprising administering to the subject the peptide of claim 1 .
3. The process according to claim 2 , wherein the neurological disorder is caused by or associated with beta-amyloid protein plaque deposition in an area of the patient.
4. The process according to claim 2 , wherein the neurological disorder is caused by, or associated with:
a) dysfunction of long-term potentiation of synaptic transmission; or
b) inflammation.
5. The process according to claim 2 , wherein the neurological disorder affects cognitive function.
6. The process according to claim 2 , wherein the neurological disorder is a neurodegenerative disorder.
7. The process according to claim 2 , wherein the neurological disorder is selected from the group consisting of clinical or pre-clinical Alzheimer's disease, and prodromal Alzheimer's disease.
8. A process for the treatment of clinical Alzheimer's Disease in a subject in need thereof comprising administering to the subject a peptide consisting of the following sequence: (a) YXEGTFTSDYSIYLDKQAAXEFVNWLLAGGPSSGAPPPSKKKKKK-NH 2 wherein X=aminoisobutyric acid (SEQ ID NO: 11); or
(b) YXEGTFTSDYSIYLDKQAAXEFVNWLLAGGPSSGAPPPSKRRQRRKKRGY-NH 2 (SEQ ID NO: 12) wherein X=aminoisobutyric acid.